Industry Supported Sessions Programs

Industry Supported Sessions Programs

WEDNESDAY, MARCH 27, 2019

INDUSTRY SESSION 1

FROM OFF TO ON - TREATING "OFF" EPISODES IN PARKINSON'S DISEASE

SYMPOSIUM IS ORGANISED AND SUPPORTED BY Sunovion

Wednesday, March 27| 11:00 - 13:00 | Auditorium I

Chair: Warren Olanow (USA)        

11:00-11:10       INTRODUCTION AND OVERVIEW

11:10–11:30      PHENOMENOLOGY AND CLINICAL SIGNIFICANCE OF "OFF" EPISODES IN PD
                         Werner Poewe (Austria)
11:30–11:50      PATHOPHYSIOLOGY AND RISK FACTORS FOR THE DEVELOPMENT OF "OFF" EPISODES IN PD
                         Warren Olanow (USA)

11:50–12:10      CURRENT APPROACHES TO THE TREATMENT OF "OFF" EPISODES IN PD
                         Olivier Rascol (France)

12:10–12:30      NEW THERAPIES FOR THE ACUTE TREATMENT OF "OFF" EPISODES IN PD
                         Fabrizio Stocchi (Italy)

12:30–13:00      PANEL DISCUSSION
                          All 


INDUSTRY SESSION 2

LIPIDIDIET: CLINICAL TRIAL RESULTS FROM THE 3-YEAR INTERVENTION WITH FORTASYN CONNECT (SOUVENAID) IN PRODROMAL AD

SYMPOSIUM IS ORGANISED AND SUPPORTED BY Nutricia

Wednesday, March 27| 15:05-15:35 | Auditorium I

Chair: Miia Kivipelto (Sweden)

15:05 – 15:10 CHAIR’S WELCOME AND INTRODUCTION 
                       Miia Kivipelto (Sweden)

15:10 - 15:20 EFFECTS OF THE SPECIFIC MULTINUTRIENT COMBINATION FORTASYN CONNECT IN PRODROMAL ALZHEIMER'S DISEASE (LIPIDIDIET): DETAILED CHARACTERISATION OF THE 36-MONTH DROPOUT PATTERN
Tobias Hartmann (Germany)

15:20- 15:35  EFFECTS OF THE SPECIFIC MULTINUTRIENT COMBINATION FORTASYN CONNECT IN PRODROMAL ALZHEIMER'S DISEASE (LIPIDIDIET): 36-MONTH INTERVENTION RESULTS
Hilkka Soininen (Finland)

To view the speaker abstracts please click here

INDUSTRY SESSION 3

TREATMENT OF A BACTERIAL PATHOGEN IN ALZHEIMER'S DISEASE BRAINS

SYMPOSIUM IS ORGANISED AND SUPPORTED BY Cortexyme

Wednesday, March 27| 15:40-16:10 | Auditorium I

15:40 - 15:55   PORPHYROMONAS GINGIVALIS IN ALZHEIMER'S DISEASE BRAINS: EVIDENCE FOR DISEASE                               CAUSATION AND TREATMENT WITH SMALL-MOLECULE INHIBITORS
                        Stephen S. Dominy (USA)

15:55- 16:10    SAFETY, PK, BIOMARKER, AND COGNITIVE READOUTS IN A PHASE IB STUDY OF COR388 AND                           PLANS FOR PHASE II/III
                        Michael J. Detke (USA)


INDUSTRY SESSION 4

CRENEZUMAB: LATE-BREAKING UPDATE ON THE CREAD PHASE 3 INTERIM ANALYSIS OUTCOME

SYMPOSIUM IS ORGANISED AND SUPPORTED BY Roche

Wednesday, March 27| 16:15-16:45 | Auditorium I

Chair: Rachelle Doody (Switzerland)

16:15 - 16:20   WELCOME AND INTRODUCTION
                       Rachelle Doody (Switzerland)

16:20- 16:35    CRENEZUMAB: LATE-BREAKING UPDATE ON THE CREAD PHASE 3 INTERIM ANALYSIS                                        OUTCOME
                        Susanne Ostrowitzki (USA)

16:35- 16:45    Q&A
                        Susanne Ostrowitzki (USA)


THURSDAY, MARCH 28, 2019

INDUSTRY SESSION 5

DETECTING AD AND PD WITH PLASMA BIOMARKERS: INNOVATIONS THAT INFORM CLINICAL PRACTICE

SYMPOSIUM IS ORGANISED AND SUPPORTED BY MagQu Co. Ltd. 

Thursday, March 28 | 09:15 - 11:15 | Auditorium I

Chair: Kaj Blennow (Sweden)      

09:15–09:20   INTRODUCTIONS AND MEETING OBJECTIVES
                      Kaj Blennow (Sweden)

09:20–09:35   PLASMA BIOMARKERS FOR AD: THE CURRENT LANDSCAPE
                      Andrea Vergallo (France)

09:35–09:50   THE IMR-SQUID TECHNOLOGY PLATFORM
                      Shieh-Yueh Yang (Taiwan)

09:50–10:10   GLOBAL VALIDATION OF THE IMR ASSAY IN AD
                      Lih-Fen Lue (USA)

10:10–10:30   CORRELATION OF THE IMR ASSAY WITH IMAGING BIOMARKERS (MRI & PET)
                      Ming-Jang Chiu (Taiwan)

10:30-10:50   DIFFERENTIAL DIAGNOSIS OF THE IMR ASSAY IN AD, PD, & FTD
                      Chin-Hsien Lin (Taiwan)

10:50-11:05   HOW PLASMA BIOMARKERS MAY INFORM CLINICAL PRACTICE
                      José Luis Molinuevo (Spain)

11:05-11:15   Q&A SESSION
                      Kaj Blennow (Sweden)


INDUSTRY SESSION 6

EARLY ALZHEIMER'S DISEASE: MEETING PATIENT AND CAREGIVER NEEDS THROUGH A MULTIDISCIPLINARY APPROACH

SYMPOSIUM IS ORGANISED AND SUPPORTED BY Roche

Thursday, March 28 | 11:45 - 13:30 | Auditorium I

Chair: Tania Dussey-Cavassini (Switzerland)

11:45 - 11:50  SYMPOSIUM ARRIVALS AND LUNCH

11:50 - 11:55  WELCOME AND INTRODUCTION
                       Tania Dussey-Cavassini (Switzerland)

11:55 - 12:05  THE CAREGIVER AND FAMILY STORY
                       Tania Dussey-Cavassini (Switzerland)

12:05 - 12:15  MEET THE PATIENT: INTERACTIVE CASE STUDY AND PANEL DISCUSSION
                       Tania Dussey-Cavassini (Switzerland)

12:15 - 12:40  THE BENEFIT OF COGNITIVE ASSESSMENTS: THE NEUROPSYCHOLOGIST'S INPUT
                       Jane Martin (USA)

12:40 - 13:00  HOW TO INCREASE DIAGNOSTIC CONFIDENCE: THE VIEW FROM A BIOMARKER EXPERT
                        Oskar Hansson (Sweden)

13:00 - 13:25  NEUROIMAGING AND THE CONFIRMATION OF DIAGNOSIS: THE NEUROLOGIST'S PERSPECTIVE
                        Marwan Sabbagh (USA)

13:25 - 13:30  A VISION OF THE FUTURE FOR ALZHEIMER'S DISEASE PATIENTS: SUMMARY AND CLOSE
                       Tania Dussey-Cavassini (Switzerland)


INDUSTRY SYMPOSIUM 7

INSIDE DEMENTIA WITH LEWY BODIES: FROM DIAGNOSIS TO CARE

SYMPOSIUM IS ORGANISED AND SUPPORTED BY Eisai

Thursday, March 28 17:20 – 19:20 | Auditorium VI+VII 

Chair: James Galvin (USA)

17:20 – 17:35    INTRODUCTION
                         James Galvin (USA)

17:35 – 18:00    NAVIGATING THE UNKNOWN OF LEWY BODY DEMENTIAS 
                         Angela Taylor (USA)

18:00 – 18:25   DEMENTIA WITH LEWY BODIES: DIAGNOSTIC ISSUES COMPARED TO ALZHEIMER’S DISEASE
                         Ian McKeith (UK)

18:25 – 18:50    RAISING AWARENESS AND WORKING COLLABORATIVELY
                         Dag Aarsland (UK)

18:50 – 19:20    Q&A SESSION
                         All

FRIDAY, MARCH 29, 2019

INDUSTRY SESSION 8

AMBAR (ALZHEIMER’S MANAGEMENT BY ALBUMIN REPLACEMENT) PHASE IIB/III RESULTS:
CLINICAL AND BIOMARKER UPDATE

SYMPOSIUM IS ORGANISED AND SUPPORTED BY Grifols
 
Friday, March 29 | 09:15-11:15 | Auditorium VI+VII
 
Chair: Jeffrey L. Cummings (USA)
 
09:15 - 09:20   INTRODUCTION AND OVERVIEW
                        Jeffrey L. Cummings (USA)
 
09:20 - 09:40   ALBUMIN AS PHARMACEUTICAL ACTIVE INGREDIENT FOR ALZHEIMER’S DISEASE
                        Montserrat Costa (SPAIN)
 
09:40 - 10:00   PILOT AND PHASE II STUDIES ON PLASMA EXCHANGE WITH ALBUMIN REPLACEMENT IN                                  ALZHEIMER’S DISEASE
                        Óscar López (USA)
 
10:00 - 10:15   THE AMBAR STUDY DESIGN
                        Mercè Boada (SPAIN)
 
10:15 - 10:40   THE AMBAR STUDY UPDATE ON EFFICACY, SAFETY AND BIOMARKER RESULTS.
                        Antonio Páez (SPAIN)
 
10:40 - 11:10   PANEL DISCUSSION AND Q&A
                        Montserrat Costa (SPAIN)
                        Óscar López (USA)
                        Mercè Boada (SPAIN)
                        Antonio Páez (SPAIN)
                   
                          
11:10 - 11:15   CONCLUDING REMARKS
                        Jeffrey L. Cummings (USA)


INDUSTRY SESSION 9


THE EARLY DIAGNOSIS OF ALZHEIMER'S DISEASE: EXPLORING PATHOLOGICAL OBSTACLES
SYMPOSIUM IS ORGANISED AND SUPPORTED BY Biogen  

Friday, March 29| 11:45–13:25 | Auditorium I

Chair: José Luis Molinuevo (Spain)

11:45–11:50    ARRIVAL AND OPTIONAL LUNCH

11:50–12:00    WELCOME AND INTRODUCTION
                        José Luis Molinuevo (Spain)

12:00–12:10    MEET OUR PATIENT: A CASE STUDY FOR DISCUSSION
                       José Luis Molinuevo (Spain)

12:10–12:30    EXPLORATION OF A COMPLEX CASE: CONDUCTING A COMPLETE CLINICAL AND COGNITIVE                               ASSESSMENT
                       Alireza Atri (USA)

12:30–12:50   SUPPORTING AN EARLY DIAGNOSIS: IDENTIFYING UNDERLYING PATHOLOGIES WITH                                           BIOMARKERS
                       Henrik Zetterberg (Sweden)

12:50–13:10    PATIENT MANAGEMENT FOLLOWING AN EARLY DIAGNOSIS: OPTIONS AND KEY                                                   CONSIDERATIONS
                       James Leverenz (USA)

13:10–13:20    PANEL DISCUSSION AND AUDIENCE Q&A
                       All

13:20–13:25    SUMMARY AND CLOSE
                        José Luis Molinuevo (Spain)


INDUSTRY SESSION 10

NOW YOU SEE ME: THE VOICE OF PEOPLE WITH PARKINSON'S DISEASE IN CLINICAL TRIALS
'A NEW ERA OF TREATING AND MEASURING TREATMENT OUTCOMES IN PD'

SYMPOSIUM IS ORGANISED AND SUPPORTED BY Roche  

Friday, March 29| 15:45 - 16:45 | Auditorium I

Chair: Bas Bloem (Netherlands)     

Patient advocate speaker: Benjamin Stecher (Canada)

15:45–15:50   INTRODUCTION 
                      Bas Bloem (Netherlands)

15:50–16:10   THE REAL FACE OF PARKINSON'S DISEASE: BRINGING PARKINSON'S DISEASE CLINICAL                                        STUDIES BACK HOME
                      Bas Bloem (Netherlands)

16:10–16:20   MY PERSONAL PARKINSON’S
 
                      Benjamin Stecher (Canada)

16:20–16:35  NO ONE CAN DO THIS ALONE
                      
Audience engagement

16:35-16:40   Q&A 
                      Bas Bloem (Netherlands) and Benjamin Stecher (Canada)

16:40-16:45   SUMMARY AND CLOSE
                      Bas Bloem (Netherlands)


INDUSTRY SESSION 11

FROM MICE TO MEN: INCREASING PREDICTIVE VALUE IN CNS DRUG DEVELOPMENT

SYMPOSIUM IS ORGANISED AND SUPPORTED BY PsychoGenics / NeuroScios 

Friday, March 29| 17:15 - 19:15 | Auditorium VI+VII

Chairs:  Manfred Windisch (AUSTRIA) and Emer Leahy (USA)         


17:15–17:35    NEXT-GENERATION MOUSE MODELS OF ALZHEIMER'S DISEASE

Gregory Carter (USA)

 

17:35–17:55    HIGH CONTENT PHENOTYPING AND MACHINE LEARNING APPROACHES TO AD DRUG DISCOVERY

Emer Leahy (USA)


17:55–18:15    INSIGHTS INTO ALTERED CNS FUNCTION BY EEG BIOMARKERS: APPLICATION TO AD DRUG DISCOVERY
Steve Leiser (USA)

 

18:15–18:35    LINKING EXPERIMENTAL MODELS OF AD TO PRECLINICAL AND CLINICAL DRUG                        DEVELOPMENT PROGRAMS

                        Eliezer Masliah (USA)

 

18:35–18:55    ADVANCED MEDICAL IMAGE HANDLING AND ANALYSIS IN CNS CLINICAL TRIALS
Matt Rowe (UK)

 

18:55-19:15     DRUG DEVELOPMENT IN AD - CHALLENGES IN CLINIC AND BEHAVIORAL TESTING
Jakub Hort (CZECH REPUBLIC)


Saturday, March 30, 2019


INDUSTRY SYMPOSIUM 12

 

ANTI-AMYLOID MONOCLONAL ANTIBODIES FOR THE TREATMENT OF ALZHEIMER’S DISEASE: NEW OPPORTUNITIES

SYMPOSIUM IS ORGANISED AND SUPPORTED BY  Eisai

Saturday, March 30 | 09:15 – 11:15 | Auditorium I

Chair: Jeffrey Cummings (USA)

09:15 – 09:30

INTRODUCTION

Jeffrey Cummings (USA)


09:30 – 09:55

TRANSLATING AMYLOID TARGETS INTO CLINICAL TRIALS

Christopher van Dyck (USA)


09:55 – 10:20

INNOVATION TO IMPROVE OUTCOMES IN CLINICAL TRIALS

Jeffrey Cummings (USA)

10:20 – 10:45

LEVERAGING BIOMARKERS IN CLINICAL TRIALS: PROGRESS AND PROSPECTS

Sebastiaan Engelborghs (Belgium)


10:45 – 11:15

Q&A SESSION

All